Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.
Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.
US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.
FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have .These have altogether been the major driving factors in the development of peptide antibiotics.
With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.
“Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.
Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.
US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.
FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have .These have altogether been the major driving factors in the development of peptide antibiotics.
With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.
1. PEPTIDE ANTIBIOTICS - A NEW ERA FOR ANTIBIOTICS
1.1 Introduction
1.2 Systemization of Peptide Antibiotics & Drugs
1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
1.2.2 Ribosomal Synthesized Peptide Antibiotics
2. MECHANISM & PRODUCTION OF PEPTIDE ANTIBIOTICS
2.1 Approach of Peptide Antibiotics on Bacterial Surface
2.2 Creational Process of Peptide Antibiotics
3. IDENTIFICATION OF HUMAN ANTIMICROBIAL PEPTIDES
3.1 Human Defensins
3.2 Human Cathelicidins
3.3 Antimicrobial Neuropeptides
4. PORTRAYAL OF PEPTIDE ANTIBIOTICS IN CANCER TREATMENT
4.1 Introduction
4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment
5. CATEGORIZATION OF ANTICANCER PEPTIDES
5.1 Alpha-Helical Anticancer Peptides
5.2 Beta-Sheet Anticancer Peptides
6. APPROVED PEPTIDE ANTIBIOTICS
6.1 Bacitracin
6.2 Viomycin
7. MARKET ANALYSIS OF PEPTIDE ANTIBIOTICS
7.1 Introduction to Antibacterial Drug Market
7.2 Global Antimicrobial Peptide Market
8. MARKET DYNAMICS OF ANTIMICROBIAL PEPTIDES
8.1 Favorable Parameters
8.2 Challenges
9. FUTURE PERSPECTIVE OF PEPTIDE ANTIBIOTICS MARKET & DRUG DEVELOPMENT
10. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE OVERVIEW
10.1 By Country
10.2 By Indication
10.3 By Mode of Action
10.4 By Formulation
10.5 By Delivery Route
11. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
12. MARKETED PEPTIDE ANTIBIOTICS CLINICAL & PATENT ANALYSIS
12.1 Telavancin (Arbelic & Vibativ)
12.2 Dalbavancin (Dalvance & Xydalba)
12.3 Daptomycin Intravenous (Cubicin)
12.4 Oritavancin (Nuvocid & ORBACTIV)
12.5 Teicoplanin (Targocid)
12.6 Vancomycin (Vancomycin hydrochloride)
13. COMPETITIVE LANDSCAPE
13.1 AMP Therapeutics
13.2 Eli Lilly
13.3 GlaxoSmithKline
13.4 Hospira
13.5 Kasten
13.6 Madam Therapeutics
13.7 Novartis
13.8 Pacgen Life Science Corporation
13.9 Pfizer
13.10 Phosphagenics
13.11 Savara Pharmaceuticals
13.12 Theravance
13.13 Vicuron Pharmaceuticals
1.1 Introduction
1.2 Systemization of Peptide Antibiotics & Drugs
1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
1.2.2 Ribosomal Synthesized Peptide Antibiotics
2. MECHANISM & PRODUCTION OF PEPTIDE ANTIBIOTICS
2.1 Approach of Peptide Antibiotics on Bacterial Surface
2.2 Creational Process of Peptide Antibiotics
3. IDENTIFICATION OF HUMAN ANTIMICROBIAL PEPTIDES
3.1 Human Defensins
3.2 Human Cathelicidins
3.3 Antimicrobial Neuropeptides
4. PORTRAYAL OF PEPTIDE ANTIBIOTICS IN CANCER TREATMENT
4.1 Introduction
4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment
5. CATEGORIZATION OF ANTICANCER PEPTIDES
5.1 Alpha-Helical Anticancer Peptides
5.2 Beta-Sheet Anticancer Peptides
6. APPROVED PEPTIDE ANTIBIOTICS
6.1 Bacitracin
6.2 Viomycin
7. MARKET ANALYSIS OF PEPTIDE ANTIBIOTICS
7.1 Introduction to Antibacterial Drug Market
7.2 Global Antimicrobial Peptide Market
8. MARKET DYNAMICS OF ANTIMICROBIAL PEPTIDES
8.1 Favorable Parameters
8.2 Challenges
9. FUTURE PERSPECTIVE OF PEPTIDE ANTIBIOTICS MARKET & DRUG DEVELOPMENT
10. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE OVERVIEW
10.1 By Country
10.2 By Indication
10.3 By Mode of Action
10.4 By Formulation
10.5 By Delivery Route
11. GLOBAL PEPTIDE ANTIBIOTICS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration
12. MARKETED PEPTIDE ANTIBIOTICS CLINICAL & PATENT ANALYSIS
12.1 Telavancin (Arbelic & Vibativ)
12.2 Dalbavancin (Dalvance & Xydalba)
12.3 Daptomycin Intravenous (Cubicin)
12.4 Oritavancin (Nuvocid & ORBACTIV)
12.5 Teicoplanin (Targocid)
12.6 Vancomycin (Vancomycin hydrochloride)
13. COMPETITIVE LANDSCAPE
13.1 AMP Therapeutics
13.2 Eli Lilly
13.3 GlaxoSmithKline
13.4 Hospira
13.5 Kasten
13.6 Madam Therapeutics
13.7 Novartis
13.8 Pacgen Life Science Corporation
13.9 Pfizer
13.10 Phosphagenics
13.11 Savara Pharmaceuticals
13.12 Theravance
13.13 Vicuron Pharmaceuticals
LIST OF FIGURES
Figure 1-1: Structure of Some Important Peptide Antibiotics
Figure 1-2: Classification & Characterization of Peptide Antibiotics
Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth
Figure 2-2: Chemical Structure of Teixobactin
Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin
Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes
Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens
Figure 4-1: Angiogenesis Inhibition Mechanism of Action
Figure 6-1: Bacitracin - Mechanism of Action
Figure 7-1: Global - Antibacterial Drug Market (US$ Billion), 2016-2023
Figure 7-2: Usage of Therapeutic Peptides & Proteins in Different Disorders (%)
Figure 7-3: Global - Peptide Drug Market (US$ Billion), 2016-2023
Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration
Figure 7-5: Global - Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global - Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide
Figure 8-2: Challenges to Antimicrobial Peptide Market Growth
Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides
Figure 10-1: Global - Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023
Figure 10-2: Global - Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023
Figure 10-3: Global - Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023
Figure 10-4: Global - Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023
Figure 10-5: Global - Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023
Figure 1-1: Structure of Some Important Peptide Antibiotics
Figure 1-2: Classification & Characterization of Peptide Antibiotics
Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth
Figure 2-2: Chemical Structure of Teixobactin
Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin
Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes
Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens
Figure 4-1: Angiogenesis Inhibition Mechanism of Action
Figure 6-1: Bacitracin - Mechanism of Action
Figure 7-1: Global - Antibacterial Drug Market (US$ Billion), 2016-2023
Figure 7-2: Usage of Therapeutic Peptides & Proteins in Different Disorders (%)
Figure 7-3: Global - Peptide Drug Market (US$ Billion), 2016-2023
Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration
Figure 7-5: Global - Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global - Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide
Figure 8-2: Challenges to Antimicrobial Peptide Market Growth
Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides
Figure 10-1: Global - Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023
Figure 10-2: Global - Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023
Figure 10-3: Global - Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023
Figure 10-4: Global - Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023
Figure 10-5: Global - Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023
LIST OF TABLES
Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides
Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets
COMPANIES MENTIONED
AMP Therapeutics,
Eli Lilly,
GlaxoSmithKline,
Hospira,
Kasten,
Madam Therapeutics,
Novartis,
Pacgen Life Science Corporation,
Pfizer,
Phosphagenics,
Savara Pharmaceuticals,
Theravance,
Vicuron Pharmaceuticals
Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides
Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets
COMPANIES MENTIONED
AMP Therapeutics,
Eli Lilly,
GlaxoSmithKline,
Hospira,
Kasten,
Madam Therapeutics,
Novartis,
Pacgen Life Science Corporation,
Pfizer,
Phosphagenics,
Savara Pharmaceuticals,
Theravance,
Vicuron Pharmaceuticals
